{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzp35p\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzp35p\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/17\\\/6\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/17\\\/6\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/17\\\/6\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/17\\\/6\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EBiosimilar drugs may offer affordable targeted therapies to patients across a spectrum of rheumatologic, oncologic, and gastrointestinal diseases, but they pose unique clinical trial design and licensing issues. Governments provide incentives for developing orphan drugs that would not otherwise be cost-effective to manufacture, allowing for the possibility of effective treatment options for rare diseases, including many rheumatologic conditions.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EInflammatory Disorders\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERheumatoid Arthritis\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ELupus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERheumatological Autoimmune Disorders\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EInflammatory Disorders\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERheumatology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERheumatoid Arthritis\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ELupus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERheumatological Autoimmune Disorders\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EBiosimilar drugs may offer affordable targeted therapies to patients across a spectrum of rheumatologic, oncologic, and gastrointestinal diseases, but they pose unique clinical trial design and licensing issues. Governments provide incentives for developing orphan drugs that would not otherwise be cost-effective to manufacture, allowing for the possibility of effective treatment options for rare diseases, including many rheumatologic conditions.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EJurgen Braun, MD, PhD, medical director of the Rheumazentrum Ruhrgebiet, Herne, Germany, defined biosimilars as products sufficiently similar to a biopharmacological product already approved by a regulatory agency [Kay J. \u003Cem\u003EArthritis Res Ther\u003C\/em\u003E 2011]. He stated that biologics revolutionized medicine, contributing significantly to better quality of life for patients with rheumatic diseases. Several points were addressed, which are summarized in this article.\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EBIOSIMILARS ARE NOT COMPARABLE TO GENERIC DRUGS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EBiosimilars are unlike generic drugs, and they are much larger, more complex structures with 4 levels of protein folding. Cellular activity is dependent on correct glycosylation; differences in glycosylation could turn an immunomodulatory antibody into a cytotoxic antibody.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EProf. Braun emphasized that biosimilars are not identical to the reference drug, and a range of structural differences may exist [Woodcock J et al. \u003Cem\u003ENature Rev Drug Discovery\u003C\/em\u003E 2007], which are allowed when there are no clinically meaningful differences in safety, purity, and potency between products [Patient Protection and Affordable Care Act. Pub L No. 111\u2013148, Section 7002 (2010)].\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EPATENT EXPIRATIONS AND ECONOMIC BENEFITS FOR MANUFACTURERS DRIVE BIOSIMILAR DEVELOPMENT\u003C\/h2\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EPatents for 5 of 9 biologic agents used in rheumatology will expire by 2015 in Europe and by 2019 in the United States. Incentives to manufacturers of biosimilars include 1-year exclusive marketing, which may be extended to 42 months [Patient Protection and Affordable Care Act. Pub L No. 111\u2013148, Section 7001 (2010)].\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003ETwo new infliximab biosimilars were approved by the European Medicines Agency (EMA) in 2013 for use in rheumatology. Seven rituximab and etanercept biosimilars are being marketed in Mexico, India, and South America that do not have EMA or US Federal Drug Administration (FDA) approval [Scheinberg MA, Kay J. \u003Cem\u003ENat Rev Rheumatol\u003C\/em\u003E 2012]. Eight rituximab biosimilars plus 13 biosimilars of adalimumab, etanercept, and infliximab are in the pipeline and in various phases of clinical trials.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ECHANGES IN MANUFACTURE OF BIOPHARMACEUTICALS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EProduction changes have resulted in decreased [Rudick RA et al \u003Cem\u003ENeurology\u003C\/em\u003E 1998] and increased immunogenicity [Bennet CL et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2005]. Prof. Braun pointed out that postapproval manufacturing changes vary by jurisdiction, but the original manufacturer has detailed information pertaining to production changes that are not available to the biosimilar manufacturer [Schneider CK \u003Cem\u003EJ Ann Rheum Dis\u003C\/em\u003E 2013]. Due to production changes, infliximab and etanercept can today be regarded as biosimilars to the compounds approved 10 years ago.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-4\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EEMA AND FDA GUIDANCE ON BIOSIMILAR STUDIES\u003C\/h2\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EEMA guidelines require biosimilar trials to demonstrate pharmacodynamic (PD) and pharmacokinetic (PK) comparability of monoclonal antibodies using \u003Cem\u003Ein vitro\u003C\/em\u003E studies; animal studies may also be required [Committee for Medicinal Products for Human Use. \u003Cem\u003EGuideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies\u003C\/em\u003E. European Medicines Agency 2012]. At least one randomized clinical trial (RCT) with double-blind, parallel-group comparative design is sufficiently powered to demonstrate therapeutic equivalence plus the collection of long-term immunogenicity and safety data of biosimilar monoclonal antibodies.\u003C\/p\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EUS regulations take a \u201ctotality of evidence approach\u201d wherein FDA scientists integrate information to make an overall assessment. According to FDA guidelines, a biosimilar agent need not be licensed for all routes of administration, all doses, or an indication for which the reference product has already obtained approval [US Department of Health and Human Services, FDA. \u003Cem\u003EGuidance for Industry. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009\u003C\/em\u003E Draft 2012]. Data from a clinical trial of a biosimilar for one disease may be extrapolated to support approval for additional indications that have been licensed for the reference. No recommendations are made for whether the trial design is noninferiority or equivalence or for the size and duration of the trial.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ECLINICAL TRIAL DESIGN SUPPORTING NEW DRUG LICENSING AND BIOSIMILARS DIFFERS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-11\u0022\u003EClinical trials of biosimilars must demonstrate equivalence to the reference within a prescribed margin; noninferiority trial design is not suitable. Biosimilar trials must use the same dose as the reference, thus eliminating the need for Phase 2 dose-ranging studies.\u003C\/p\u003E\n         \u003Cp id=\u0022p-12\u0022\u003ERemicade (infliximab) biosimilar CT-P13 began with \u003Cem\u003Ein vitro\u003C\/em\u003E comparability studies of the primary and secondary mechanism of action (MOA) to demonstrate comparable Fc binding. A Phase 1 double-blind, randomized, controlled trial (RCT) of CT-P13 versus Remicade\u00ae in ankylosing spondylitis followed; the primary endpoint was the ratio of geometric means of PK parameters of both agents at Weeks 22 and 30 [Park W et al. \u003Cem\u003EJ Ann Rheum Dis\u003C\/em\u003E 2013].\u003C\/p\u003E\n         \u003Cp id=\u0022p-13\u0022\u003EA Phase 3, double-blind RCT of CT-P13 versus Remicade\u00ae was then conducted with 606 patients with active rheumatoid arthritis; the primary end point was the proportion of patients achieving American College of Rheumatology (ACR20) response at Week 30, and secondary end points were the proportion of patients with ACR50 and ACR70 and the frequency of adverse events. All parameters were comparable among all time points [Yoo D et al. \u003Cem\u003EJ Ann Rheum Dis\u003C\/em\u003E 2013].\u003C\/p\u003E\n         \u003Cp id=\u0022p-14\u0022\u003EDifferences in the pharmacodynamics of clinical response rates were, however, demonstrated at 4, 8, and 12 weeks in drugs that had identical response rates at 30 weeks, showing the need for more careful monitoring by incorporating more frequent, early time points [Kay J et al. \u003Cem\u003EJ Ann Rheum Dis\u003C\/em\u003E 2013].\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EEXTRAPOLATED DATA MAY BE USED TO SUPPORT BIOSIMILAR USE\u003C\/h2\u003E\n         \u003Cp id=\u0022p-15\u0022\u003EBiosimilars may be used in diseases for which the reference drug has been approved after demonstrating comparable therapeutic effects. Ankylosing spondylitis, psoriatic arthritis, and Crohn\u0027s disease are treated with tumor necrosis factor inhibitors; extrapolated data could be used to allow biosimilars to treat these conditions.\u003C\/p\u003E\n         \u003Cp id=\u0022p-16\u0022\u003ERemsima, the first EMA-approved infliximab biosimilar, demonstrated impressive comparability with minor differences that the EMA determined were not clinically relevant. Nevertheless, postmarketing studies are required to confirm the efficacy and safety of the extrapolated indication.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ECONCERNS REGARDING BIOSIMILAR USE FOR PATIENTS AND RHEUMATOLOGISTS: SWITCHING VERSUS SUBSTITUTION OF BIOSIMILARS MAY REQUIRE FURTHER TESTING\u003C\/h2\u003E\n         \u003Cp id=\u0022p-17\u0022\u003ENo guidance exists on switching, in which patients are transitioned to a biosimilar following initial treatment with reference, and substitution, in which the biosimilar is considered to be interchangeable; substitution could be made by the pharmacist without input from the prescriber.\u003C\/p\u003E\n         \u003Cp id=\u0022p-18\u0022\u003ETrials are needed to investigate the effects of a single switch versus repeated switching; switching to a biosimilar could adversely affect patients, and only one trial has been performed. Frequent switching should not be allowed because subtle differences introduced during processing could trigger an immune response.\u003C\/p\u003E\n         \u003Cp id=\u0022p-19\u0022\u003EIt is likely that biosimilar availability will reduce the cost of targeted therapies for patients; Prof. Braun explained that the social contract mandates that the potential risk to the individual of switching to a biosimilar be weighed against the societal benefit of lower cost that extends care to more patients.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-8\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EORPHAN DRUGS IN RHEUMATOLOGIC DISEASES\u003C\/h2\u003E\n         \u003Cp id=\u0022p-20\u0022\u003EJonathan Kay, MD, University of Massachusetts Medical School, Boston, Massachusetts, USA, defined an orphan drug as one that is used to treat rare diseases having \u0026lt;200,000 people in the United States and \u0026lt;250,000 in the European Union [FDA. \u003Ca href=\u0022http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm364750.htm\u0022\u003Ehttp:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm364750.htm\u003C\/a\u003E. Accessed July 14, 2014; EMA. \u003Ca href=\u0022http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000034.jsp\u0022\u003Ehttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000034.jsp\u003C\/a\u003E. Accessed July 14, 2014]. Rare diseases affect 5000 to 8000 people, and 80% have a genetic origin.\u003C\/p\u003E\n         \u003Cp id=\u0022p-21\u0022\u003EThe Orphan Drug Act in the United States and Orphan Regulation in the European Union were necessitated by the small number of people with rare diseases that made drug development unattractive to drug companies. Therapeutics have not been developed for rare diseases because companies manufacturing an orphan drug have small sales revenue relative to the development cost.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-9\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EANTICIPATED FINANCIAL LOSSES CAUSED REGULATORY AGENCIES TO PROVIDE FINANCIAL INCENTIVES TO DRUG COMPANIES\u003C\/h2\u003E\n         \u003Cp id=\u0022p-22\u0022\u003EIncentives for orphan drug development in the United States include tax credits for the cost of clinical research, annual federal grant funding for the costs of clinical testing, aid in designing clinical trials, 7 years of exclusive marketing protection following the development and approval of an orphan drug, and waiver of filing fees [FDA Consumer Health Information \u003Cem\u003EDeveloping Orphan Products: FDA and Rare Disease Day\u003C\/em\u003E 2009].\u003C\/p\u003E\n         \u003Cp id=\u0022p-23\u0022\u003EThe European Union also offers funded research grants, access to centralized marketing procedures, protocol assistance, 10 years of exclusive marketing following approval, reductions of 50% for marketing fees, and fee waiver of protocol assistance and preauthorization inspection fees [Hughes B et al. \u003Cem\u003ENat Rev Drug Discov\u003C\/em\u003E 2008].\u003C\/p\u003E\n         \u003Cp id=\u0022p-24\u0022\u003ESince 1983, the FDA has designated 3088 products as orphan drugs and approved 455 orphan drugs for use in rare diseases. The European Commission has designated \u0026gt;1000 drugs as orphan medicinal products and approved 104 orphan drugs for rare diseases [European Commission Public Health. \u003Ca href=\u0022http:\/\/ec.europa.eu\/health\/human-use\/orphan-medicines\/index_en.htm\u0022\u003Ehttp:\/\/ec.europa.eu\/health\/human-use\/orphan-medicines\/index_en.htm\u003C\/a\u003E].\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-10\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EREQUIREMENTS FOR ORPHAN DRUG STATUS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-25\u0022\u003EOrphan drug designation may be requested for a previously unapproved drug or as a new use for a currently approved drug. Orphan drug status may be granted for the same drug and the same rare disease if the respective sponsors file separate applications [\u003Ca href=\u0022http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/Howtoapplyfor|OrphanProductDesignation\/ucm356481.htm\u0022\u003Ehttp:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/Howtoapplyfor|OrphanProductDesignation\/ucm356481.htm\u003C\/a\u003E]. Obtaining orphan drug status does not alter standard regulatory requirements; safety and efficacy must be demonstrated in adequate well-controlled trials.\u003C\/p\u003E\n         \u003Cp id=\u0022p-26\u0022\u003EThe EMA and FDA applications require documentation that the prevalence of the disease is below the statutory threshold and that the sponsor has no reasonable expectation that research and developments costs can be recovered by sales of the drug [\u003Ca href=\u0022http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm124795.htm#\u0022\u003Ehttp:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation\/ucm124795.htm#\u003C\/a\u003E]. Scientific need for the drug must be established, including a discussion on the medical plausibility of using the drug for the specific indication. Clinical trial data supporting the expected efficacy of the indication must be included, if it exists. When no human trial data exist, preclinical data in animal models testing the active moiety or molecular structure may be used. The application must include all data from \u003Cem\u003Ein vitro\u003C\/em\u003E studies, preclinical efficacy animal studies, clinical experience with the drug in the rare disease, and a summary of the worldwide regulatory status and marketing history of the drug.\u003C\/p\u003E\n         \u003Cp id=\u0022p-27\u0022\u003EOrphan drug incentives and benefits have resulted in many drugs being developed and approved for rare diseases that address the unmet need to treat patients with rheumatologic diseases of low prevalence. Dr. Kay underscored that treatment for many of these rare diseases would not be available without the intervention of the EU and US regulatory agencies.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/17\/6.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzp35p\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}